299 related articles for article (PubMed ID: 31451114)
1. A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.
Wang Y; Zhang Y; Ru Z; Song W; Chen L; Ma H; Sun L
J Nanobiotechnology; 2019 Aug; 17(1):91. PubMed ID: 31451114
[TBL] [Abstract][Full Text] [Related]
2. A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy.
Xu C; Song R; Lu P; Chen J; Zhou Y; Shen G; Jiang M; Zhang W
Int J Nanomedicine; 2020; 15():65-80. PubMed ID: 32021165
[TBL] [Abstract][Full Text] [Related]
3. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
[TBL] [Abstract][Full Text] [Related]
4. A pH/ROS cascade-responsive and self-accelerating drug release nanosystem for the targeted treatment of multi-drug-resistant colon cancer.
Chang N; Zhao Y; Ge N; Qian L
Drug Deliv; 2020 Dec; 27(1):1073-1086. PubMed ID: 32706272
[TBL] [Abstract][Full Text] [Related]
5. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
[TBL] [Abstract][Full Text] [Related]
6. Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic.
Pearce AK; Simpson JD; Fletcher NL; Houston ZH; Fuchs AV; Russell PJ; Whittaker AK; Thurecht KJ
Biomaterials; 2017 Oct; 141():330-339. PubMed ID: 28711780
[TBL] [Abstract][Full Text] [Related]
7. ROS-Activated homodimeric podophyllotoxin nanomedicine with self-accelerating drug release for efficient cancer eradication.
Liang B; Zhou D
Drug Deliv; 2021 Dec; 28(1):2361-2372. PubMed ID: 34747277
[TBL] [Abstract][Full Text] [Related]
8. A positive feedback strategy for enhanced chemotherapy based on ROS-triggered self-accelerating drug release nanosystem.
Hu JJ; Lei Q; Peng MY; Zheng DW; Chen YX; Zhang XZ
Biomaterials; 2017 Jun; 128():136-146. PubMed ID: 28325685
[TBL] [Abstract][Full Text] [Related]
9. Dual-responsive doxorubicin-loaded nanomicelles for enhanced cancer therapy.
Zhang X; Zhu T; Miao Y; Zhou L; Zhang W
J Nanobiotechnology; 2020 Sep; 18(1):136. PubMed ID: 32972412
[TBL] [Abstract][Full Text] [Related]
10. A dual-amplified ROS-responsive nanosystem with self-accelerating drug release for synergistic chemotherapy.
Li J; Zong Q; Zhao Z; Yuan Y
Chem Commun (Camb); 2023 Mar; 59(21):3142-3145. PubMed ID: 36811610
[TBL] [Abstract][Full Text] [Related]
11. Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA).
Patil Y; Shmeeda H; Amitay Y; Ohana P; Kumar S; Gabizon A
Nanomedicine; 2018 Jun; 14(4):1407-1416. PubMed ID: 29680672
[TBL] [Abstract][Full Text] [Related]
12. pH/ROS dual-responsive supramolecular polypeptide prodrug nanomedicine based on host-guest recognition for cancer therapy.
Ding Y; Wang C; Ma Y; Zhu L; Lu B; Wang Y; Wang J; Chen T; Dong CM; Yao Y
Acta Biomater; 2022 Apr; 143():381-391. PubMed ID: 35272024
[TBL] [Abstract][Full Text] [Related]
13. A tumor-specific ROS self-supply enhanced cascade-responsive prodrug activation nanosystem for amplified chemotherapy against multidrug-resistant tumors.
Wang J; Zhang H; Lv J; Zheng Y; Li M; Yang G; Wei X; Li N; Huang H; Li T; Qin X; Li S; Wu C; Zhang W; Liu Y; Yang H
Acta Biomater; 2023 Jul; 164():522-537. PubMed ID: 37072069
[TBL] [Abstract][Full Text] [Related]
14. Integrated block copolymer prodrug nanoparticles for combination of tumor oxidative stress amplification and ROS-responsive drug release.
Yin W; Ke W; Chen W; Xi L; Zhou Q; Mukerabigwi JF; Ge Z
Biomaterials; 2019 Mar; 195():63-74. PubMed ID: 30612064
[TBL] [Abstract][Full Text] [Related]
15. PSMA-mediated endosome escape-accelerating polymeric micelles for targeted therapy of prostate cancer and the real time tracing of their intracellular trafficking.
Gao Y; Li Y; Li Y; Yuan L; Zhou Y; Li J; Zhao L; Zhang C; Li X; Liu Y
Nanoscale; 2015 Jan; 7(2):597-612. PubMed ID: 25419788
[TBL] [Abstract][Full Text] [Related]
16. A pH/ROS-responsive, tumor-targeted drug delivery system based on carboxymethyl chitin gated hollow mesoporous silica nanoparticles for anti-tumor chemotherapy.
Ding X; Yu W; Wan Y; Yang M; Hua C; Peng N; Liu Y
Carbohydr Polym; 2020 Oct; 245():116493. PubMed ID: 32718608
[TBL] [Abstract][Full Text] [Related]
17. ROS-responsive liposomes with NIR light-triggered doxorubicin release for combinatorial therapy of breast cancer.
Yi H; Lu W; Liu F; Zhang G; Xie F; Liu W; Wang L; Zhou W; Cheng Z
J Nanobiotechnology; 2021 May; 19(1):134. PubMed ID: 33975609
[TBL] [Abstract][Full Text] [Related]
18. pH and ROS sequentially responsive podophyllotoxin prodrug micelles with surface charge-switchable and self-amplification drug release for combating multidrug resistance cancer.
Li C; Wang Y; Zhang S; Zhang J; Wang F; Sun Y; Huang L; Bian W
Drug Deliv; 2021 Dec; 28(1):680-691. PubMed ID: 33818237
[TBL] [Abstract][Full Text] [Related]
19. Self-immolative polyprodrug-based tumor-specific cascade amplificated drug release nanosystem for orchestrated synergistic cancer therapy.
Wang K; Xiao X; Liu Y; Zong Q; Tu Y; Yuan Y
Biomaterials; 2022 Oct; 289():121803. PubMed ID: 36150300
[TBL] [Abstract][Full Text] [Related]
20. A PSMA-targeted doxorubicin small-molecule drug conjugate.
Yoon H; Savoy EA; Mesbahi N; Hendricksen AT; March GL; Fulton MD; Backer BS; Berkman CE
Bioorg Med Chem Lett; 2024 May; 104():129712. PubMed ID: 38521177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
